BMRN
BioMarin Pharmaceuticals Inc
stockNASDAQ
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 56.63 | 2026-10-22 | +1.48% | 0.742 |
| 1M | 59.87 | 2026-09-29 | -4.01% | -0.416 |
| 3M | 61.37 | 2026-07-29 | -6.36% | 0.184 |
| 6M | 54.21 | 2026-04-29 | +6.01% | -0.018 |
| 1Y | 51.86 | 2025-10-29 | +10.82% | 0.360 |
| 2Y | 69.91 | 2024-10-29 | -17.79% | — |
| 5Y | 79.23 | 2021-10-29 | -27.46% | 0.673 |
BioMarin Pharmaceuticals Inc (NASDAQ:BMRN) stock price today is $57.47, and today's volume is 1,653,267. BMRN is up 2.625% today. The 30 day average volume is 2.37M. BMRN market cap is $11.12B with 193.57M shares outstanding.